Granicip

🧾 Product Overview Table

🧪 Introduction

Granicip 1mg by Cipla Limited is a fast-acting oral disintegrating tablet formulation of Granisetron, a highly selective serotonin 5-HT3 receptor antagonist. It is primarily used for the prevention and treatment of nausea and vomiting associated with chemotherapy and radiotherapy. As a next-generation antiemetic, Granicip blocks the action of serotonin, a natural substance that may cause vomiting.

This medicine is especially beneficial for cancer patients undergoing aggressive treatment plans, helping maintain comfort and reducing treatment-related complications. Cipla, founded in 1935, ensures globally compliant manufacturing and exports pharmaceuticals worldwide.

🎥 Educational Video

👩‍⚕️ Doctor’s Expert Insight

Dr. Kavita Desai, Oncologist:
“Granisetron is a highly tolerable antiemetic with fewer sedative effects compared to older medications. Granicip 1mg DT is a trusted choice for patients on emetogenic chemotherapy.”

💉 Dosage & Administration

⚠️ Side Effects, Storage & Precautions

• ❌ Common Side Effects: Headache, constipation, fatigue
• ⛔ Serious Reactions: QT prolongation, allergic reactions (rare)
• ❄️ Storage: Store in a cool, dry place below 25°C
• ⚠️ Precautions: Not recommended for children under 2 years; monitor ECG in patients with heart conditions

🌍 Global Availability & Pricing

🔗 Related Indian Alternatives (Different Molecules in Same Category)

📖 Trusted External References

• Drugs.com – Granisetron
• FDA Prescribing Info
• NHS – Antiemetics
• WHO Essential Medicines

⚕️ Medical Disclaimer
This content is for informational purposes only and does not replace professional medical consultation. Always consult your healthcare provider before starting any medication.